2021
MP45-05 IMPACT OF ELEVATED C-REACTIVE PROTEIN ON SURVIVAL OUTCOMES IN SMALL RENAL MASSES: ANALYSIS OF THE INMARC REGISTRY
Meagher M, Patil D, Saito K, Patel D, Javier-Desloges J, Ghali F, Hakimi K, Soliman S, Yuan J, Wan F, Fujii Y, Master V, Derweesh I. MP45-05 IMPACT OF ELEVATED C-REACTIVE PROTEIN ON SURVIVAL OUTCOMES IN SMALL RENAL MASSES: ANALYSIS OF THE INMARC REGISTRY. Journal Of Urology 2021, 206: e804-e804. DOI: 10.1097/ju.0000000000002066.05.Peer-Reviewed Original Research
2020
PD11-09 ELEVATED C-REACTIVE PROTEIN IS ASSOCIATED WITH POSTOPERATIVE DEVELOPMENT OF PROTEINURIA AND SUBSEQUENT RENAL FUNCTIONAL DECLINE AND MORTALITY
Meagher* M, Hamilton Z, Patil D, Saiko K, Bradshaw A, Patel S, Cotta B, Davaro-Comas F, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. PD11-09 ELEVATED C-REACTIVE PROTEIN IS ASSOCIATED WITH POSTOPERATIVE DEVELOPMENT OF PROTEINURIA AND SUBSEQUENT RENAL FUNCTIONAL DECLINE AND MORTALITY. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000845.09.Peer-Reviewed Original ResearchElevated C-reactive proteinC-reactive proteinRenal FunctionalPostoperative developmentProteinuriaMortality
2016
Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child
Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud R, Tebben P. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Osteoporosis International 2016, 27: 2379-2382. PMID: 26892041, DOI: 10.1007/s00198-016-3528-4.Peer-Reviewed Case Reports and Technical NotesConceptsZoledronic acidPediatric patientsMethodsA 7-year-old boyInfusion of zoledronic acidModerate acute respiratory distress syndromeNon-infective systemic inflammatory response syndromeIncreased bone mineral densitySystemic inflammatory response syndromeElevated C-reactive proteinAcute respiratory distress syndromeIntensive cardiorespiratory supportZoledronic acid infusionAbnormal coagulation profileZoledronic acid therapyHypoxic-ischemic encephalopathyPediatric intensive care unitEnd-organ dysfunctionZoledronic acid administrationInflammatory response syndromeBone mineral densityRespiratory distress syndromeRisk of fractureC-reactive proteinIncreased oxygen requirementIntensive care unit
2009
Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity.
Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Patil S, Winer E, Norton L, Hudis C, Dang C. Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity. Cancer Research 2009, 69: 3088-3088. DOI: 10.1158/0008-5472.sabcs-09-3088.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureC-reactive proteinEarly breast cancerBiomarkers of cardiotoxicityMinimal elevationEvidence of CHFElevated C-reactive proteinTroponin IDose-dense doxorubicinSensitive inflammatory markerAnti-HER2 agentsVentricular ejection fractionPre-planned analysisCardiac troponin IElevated TnIUncontrolled arrhythmiaWeekly paclitaxelInflammatory markersMUGA scanUnstable anginaEjection fractionHeart failureRecent MIProspective study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply